Quantifying how Single Dose Ad26.COV2.S Vaccine Efficacy Depends on Spike Sequence Features
The phase 3 ENSEMBLE trial of a single dose of Janssen’s Ad26.COV2.S vaccine showed an overall vaccine efficacy of 56% against symptomatic COVID-19. Looking at the Spike sequences of infecting viruses reveals a more complex picture.